Compare Jones Lang LaSalle Inc (JLL) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Jones Lang LaSalle Inc vs ResMed Inc. — how do they compare? Jones Lang LaSalle Inc trades at $303.6 (market cap $13.95B), while ResMed Inc. trades at $225.92 (market cap $31.89B). The key difference: ResMed Inc. is far larger — about 2.3× Jones Lang LaSalle Inc's market cap, and ResMed Inc. pays a 1.16% dividend while Jones Lang LaSalle Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Jones Lang LaSalle Inc for 71 Days and ResMed Inc. for 51 Days on average.
| JLL | RMD | |
|---|---|---|
Market Cap | $13.95B | $31.89B |
Volume | 457,462 | 618,314 |
Sector | Real Estate | Health |
52-Week High | $392.79 | $277.88 |
52-Week Low | $280.16 | $182.82 |
Typical Hold Time | 71 Days | 51 Days |
Enterprise Value | $16.71B | $31.24B |
Dividend Yield | — | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JLL trades at $296.66, down 2.29% over 24 hours, with a bearish technical signal from moving averages and oscillators. The stock shows strong fundamentals with a P/E of 14.54, P/S of 0.53, and net income margin of 3.64%. Recent earnings have consistently beaten expectations, and cash flow from operations reached $1.19 billion in 2025. Analyst consensus is bullish with a $450.50 price target, supported by positive news on acquisitions and growth prospects.
The outlook for JLL is positive due to robust earnings growth, improving profit margins, and strategic acquisitions. Risks include market volatility, competitive pressures in real estate services, and economic sensitivity. Institutional sentiment remains strong, with a majority of analysts recommending buy. The stock presents a value opportunity if it can sustain its operational momentum amid broader market headwinds.
ResMed (RMD) trades at $225.98, up 2.4% today, with a bullish technical signal and strong fundamentals. Revenue grew to $5.15B in 2025, with net income at $1.40B and a 26.94% net margin. Recent earnings beats and a 12-14% EPS growth outlook support momentum. The stock is near its pivot point of $227, with support at $225 and resistance at $228.
Outlook is positive with analyst consensus at Buy and a $242.70 price target. Risks include competitive pressures and ongoing legal investigations. Institutional buying and solid cash flow growth underpin the bullish case, though macroeconomic and regulatory factors warrant monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Jones Lang LaSalle Inc
Jones Lang LaSalle provides a wide range of real estate-related services to owners, occupiers, and investors worldwide, including leasing, property and project management, and capital markets advisory. JLL's investment management arm, LaSalle Investment Management, manages over $70 billion for clients across diverse public and private real estate strategies.
Read more on JLL →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
